Overview
- The Micro-Cap Composite returned 11.7% net versus 19.9% for its Russell benchmark, while the Mid Cap Composite fell 3.2% net against a 2.8% gain for the Russell Midcap Growth Index.
- Verisk shares pulled back after the company announced a $2.5 billion purchase of AccuLynx at roughly 15 times revenue, alongside moderating organic growth expectations for the back half of 2025.
- Twist Bioscience faced softer demand from biotech and academic customers, slower orders tied to tighter biopharma funding, investment-driven margin pressure, and ongoing cash burn concerns.
- IDEXX outperformed on strong quarterly results, with faster organic revenue growth and rapid uptake of its latest premium diagnostic instrument.
- Conestoga exited FactSet, citing slower organic growth, intensifying competition, margin pressures from technology and content costs, and a premium valuation that left little cushion for execution risk.